(S1 (S (S (NP (NN Angiogenin)) (VP (VP (VBZ is) (VP (VBN up-regulated) (PP (IN in) (NP (NP (DT the) (NP (NP (NN nucleus)) (CC and) (NP (NN cytoplasm)))) (PP (IN in) (NP (JJ human) (JJ primary) (NN breast) (NN carcinoma))))))) (CC and) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NNS markers)) (PP (IN of) (NP (NP (NN hypoxia)) (CONJP (CC but) (RB not)) (NP (NN survival)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Angiogenin)) (, ,) (NP (NP (DT a) (CD 14.2) (NN kD) (NN polypeptide)) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (ADVP (RB originally)) (VP (VBN noted) (PP (IN for) (NP (PRP$ its) (JJ angiogenic) (NN activity)))))))) (, ,)) (VP (VBZ is) (ADVP (RB now)) (ADVP (RB increasingly)) (VP (VBN recognized) (S (VP (TO to) (VP (VB have) (NP (NP (DT a) (NN multiplicity)) (PP (IN of) (NP (JJ biological) (NNS roles)))) (PP (IN in) (NP (ADJP (CC both) (ADJP (JJ physiological)) (CC and) (ADJP (JJ pathological))) (NNS conditions))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN breast) (NN cancer))) (, ,) (NP (EX there)) (VP (VBP are) (NP (NP (VBG conflicting) (NNS studies)) (VP (VBG questioning) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN angiogenin)))))))) (. .)))
(S1 (S (ADVP (RB Here)) (, ,) (NP (NP (DT the) (NN pattern)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NN angiogenin))))) (PP (IN during) (NP (NP (DT the) (NN transition)) (PP (IN from) (NP (JJ normal) (NN breast) (NN tissue))) (PP (TO to) (NP (NP (NP (JJ ductal) (NN carcinoma)) (ADJP (FW in) (FW situ))) (CC and) (NP (JJ invasive) (NN carcinoma))))))) (VP (VBZ is) (VP (VBN reported) (PP (ADVP (RB together)) (IN with) (NP (NP (NP (DT the) (NNS correlates)) (PP (IN between) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN angiogenin))) (PP (IN in) (NP (NP (CD 239) (JJ invasive) (NNS carcinomas)) (CC and) (NP (JJ standard) (JJ clinicopathological) (NNS parameters))))))) (, ,) (NP (NP (NP (JJ hypoxia-inducible) (NN factor) (-LRB- -LRB-) (NN HIF) (-RRB- -RRB-) (CD -1)) (NN alpha)) (CC and) (NP (NP (DT the) (NN HIF-1) (NN alpha) (NN target) (NN gene)) (NN DEC-1))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBZ shows) (SBAR (SBAR (IN that) (S (NP (NN angiogenin) (NN expression)) (VP (VBZ is) (VP (VBN up-regulated) (PP (IN in) (NP (NP (DT the) (ADJP (ADJP (JJ cytoplasmic)) (CC and) (ADJP (JJ nuclear))) (NNS compartments)) (PP (IN in) (NP (NP (ADJP (FW in) (FW situ)) (NN carcinoma)) (CC and) (NP (JJ invasive) (NN carcinoma)))))) (PP (VBN compared) (PP (IN with) (NP (JJ normal) (NN breast) (NN tissue)))))))) (CC and) (SBAR (IN that) (S (NP (NP (NN angiogenin) (NN expression)) (PP (IN in) (NP (JJ invasive) (NNS carcinomas)))) (VP (VBZ is) (VP (ADVP (RB significantly) (RB positively)) (VP (VBN associated) (PP (PP (IN with) (NP (NP (NP (NP (JJ high) (NN tumour) (NN grade)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.03)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ positive) (NN oestrogen) (NN receptor) (-LRB- -LRB-) (NN ER) (-RRB- -RRB-) (NN status)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.01)) (-RRB- -RRB-))) (, ,) (NP (NP (NN HIF-1) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.001)) (-RRB- -RRB-))) (CC and) (NP (NNP DEC) (CD 1))) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.001)) (-RRB- -RRB-)))) (, ,) (CC but) (PP (RB not) (IN with) (NP (NP (NP (NN patient) (NN age)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.8)) (-RRB- -RRB-))) (, ,) (NP (NP (NN tumour) (NN size)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.25)) (-RRB- -RRB-))) (, ,) (NP (NP (NN lymph) (NN node) (NN status)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.69)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.56)) (-RRB- -RRB-))) (CC or) (NP (NN microvessel) (NN density))))) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.32)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN difference)) (PP (IN in) (NP (NP (NP (JJ relapse-free)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.26)))) (-RRB- -RRB-))) (CC or) (NP (NP (JJ overall)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.63)))) (-RRB- -RRB-))) (NP (NN survival))))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN stratified) (PP (IN by) (NP (NN angiogenin) (NN expression))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBZ suggests) (SBAR (SBAR (IN that) (S (NP (NN angiogenin)) (VP (MD may) (VP (VB be) (ADJP (JJ important) (PP (IN in) (NP (NN breast) (NN cancer) (NN progression)))))))) (CC and) (SBAR (IN that) (S (, ,) (PP (IN through) (NP (NP (PRP$ its) (NN relationship)) (PP (IN with) (NP (NN ER))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN target)) (PP (IN for) (NP (NN tamoxifen))))))))))) (. .)))
